The Established Rheumatoid Arthritis Cohort

IRB Number: 14093

Institutional Review Board, Hospital for Special Surgery

March 17, 2015

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

Susan M. Goodman, MD 


Vivian P. Bykerk, BSc, MD, FRCPC
Dalit Ashany, MD


The HSS Rheumatoid Arthritis Cohort is a group of patients who have been diagnosed with rheumatoid arthritis, have indicated an interest in taking part in a future research study, and would like to learn about research studies or projects about rheumatoid arthritis.
Patients enrolled in the RA Cohort are informed about research studies in the IAC for which they may be eligible.
Joining the HSS Rheumatoid Arthritis Cohort would in no way interfere with your regular care. Inclusion in the cohort means that a patient is willing to be contacted about an appropriate study in the future, given their clinical characteristics. Patients are under no obligation to ever participate in any study.

Inclusion/Exclusion Criteria

Patients with a diagnosis of rheumatoid arthritis and who meet the 1987 ACR or 2010 ACR/EULAR rheumatoid arthritis classification criteria are eligible to join the Cohort.

Contact Information

Caroline Reidy

Elli Kim